NCT06181916 (VSS) is a NA clinical trial of Amp in HIV Infections, sponsored by Sentient Research.

Who is sponsoring NCT06181916?

NCT06181916 is sponsored by Sentient Research.

What drugs are being tested in NCT06181916?

Interventions in NCT06181916: Amp.

What condition does NCT06181916 study?

NCT06181916 studies HIV Infections.

Is NCT06181916 still recruiting?

NCT06181916 is currently status unknown. Last updated 24 April 2024.

Last reviewed 2024-04-24 · How we verify

NCT06181916: VSS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quantitative and Qualitative Research for "mHealth Program to Support People Living With HIV Across the HIV Care Continuum"

Status unknown NA Last updated 24 April 2024

What this trial tests

NA trial testing Amp in HIV Infections in 300 participants. Status unknown.

Timeline

29 April 2024

Primary endpoint
30 November 2024

30 December 2024

Quick facts

Lead sponsor	Sentient Research
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	29 April 2024
Primary completion	30 November 2024
Estimated completion	30 December 2024
Sites	1 location across United States

Drugs / interventions tested

Amp — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Sentient Research

Who can join

Adults 18 to 29, male only, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized control trial (RCT) is to assess the effectiveness of Amp, a mobile health (mHealth) app designed to improve outcomes along the HIV care continuum for young Black men who have sex with men (YBMSM) living with HIV. HIV care continuum (linkage to care, retention, viral suppression), quality of life and self efficacy outcomes will be compared after a 4-month period between the intervention group (use Amp and standard of care) and the control group (standard of care only).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06181916 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sentient Research
Last refreshed: 24 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06181916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing